Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Carcinoma in Situ 2 Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Oropharyngeal Neoplasms 1 Lymphoma, Follicular 1 Leukemia, Hairy Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Burkitt Lymphoma 1 Anus Neoplasms 1

Interventions

Cyclophosphamide 34 Vincristine 23 Methotrexate 21 blinatumomab 20 Prednisone 20 Specimen Handling 19 Cytarabine 18 merphos 16 prednylidene 15 deltacortene 15 Mercaptopurine 15 Doxorubicin 15 Dexamethasone 15 Biopsy 15 pegaspargase 13 N,N-dicyclohexyl-isoborneol-10-sulfonamide 13 azathiopurine 12 Rituximab 12 Etoposide 12 dexamethasone acetate 11 dexamethasone 21-phosphate 11 auricularum 11 Spinal Puncture 11 Leucovorin 11 Calcium Dobesilate 11 Asparaginase 11 fludarabine 10 Thioguanine 9 Magnetic Resonance Spectroscopy 9 Inotuzumab Ozogamicin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × Diphenhydramine × 90 days × Clear all

NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡